Persistent COVID-19 Symptoms in Minia

January 19, 2025 updated by: Marwa Kamal Ahmed Tolba, Fayoum University

Persistent COVID-19 Symptoms in Minia, Upper Egypt: an Observational Cross-sectional Study

Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them.

Study Overview

Status

Completed

Conditions

Detailed Description

This is a cross-sectional observational retrospective study. The study population included patients, both hospitalized and non-hospitalized, who were diagnosed with COVID-19. Demographic information, symptom severity, present comorbidities, and persistent COVID-19 symptoms were collected. SPSS software was used for the statistical analysis, and p-values less than 0.05 were considered significant.

Study Type

Observational

Enrollment (Actual)

189

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Fayoum, Egypt, 63111
        • Marwa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

This is a cross-sectional observational retrospective survey study in which we collected information about any persistent or new symptoms after recovery from COVID-19. The average time after recovery from COVID was 6 months at the time of patient interviews, and the median duration of symptoms was 14 days. We collected various patient data including their medical history before COVID-19, treatments they received during their illness, and self-reported use of unprescribed antibiotics in home-isolated patients.

Description

Inclusion Criteria:

- Inclusion criteria Patients were included in this study if they tested positive for COVID-19 at the time of their illness (positive COVID-19 polymerase chain reaction [PCR] test) or if laboratory, clinical, and radiological criteria suggested the infection with COVID-19, and the severity of their symptoms ranged from asymptomatic to severe. Both hospitalized and non-hospitalized patients were included.

Exclusion Criteria:

Exclusion criteria Patients excluded were frail or at the end of their life or had severe cognitive dysfunction, as well as patients <18 years of age.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Long COVID-19 has been an increasingly prevalent concern in the medical community for the last two years and is still a burden on the healthcare system worldwide
Time Frame: 2years
Constitutional and neurological manifestations are two of the most persistent symptoms. Lack of appropriate levels of awareness about long COVID-19, as well as the tendency of patients in this demographic to self-medicate are leading causes of the underreporting of long COVID-19 symptoms in this region
2years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fayoum University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 10, 2021

Primary Completion (Actual)

September 10, 2023

Study Completion (Actual)

September 10, 2024

Study Registration Dates

First Submitted

January 19, 2025

First Submitted That Met QC Criteria

January 19, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 19, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • : Persistent COVID-19 symptoms

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe